Orchid receives USFDA node for new drug

Orchid receives USFDA node for new drug

Mumbai: Orchid Chemicals & Pharmaceuticals today said it has received US administration approval for a drug used for the treatment of acute mania, manic episodes.

The company has received approval from the US Food and Drug Administration for Divalproex Sodium Delayed, Orchid Chemicals & Pharmaceuticals said in a filing to the Bombay Stock Exchange.

Mania is a severe medical condition characterised by extremely elevated mood, energy, unusual thought patterns and sometimes psychosis. Divalproex Sodium Delayed-release tablets will be available in strengths 125 mg, 250 mg and 500 mg, the filing added.

Shares of the company were trading at Rs84, up 3% on the BSE.

Close